Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Archives of Biochemistry and Biophysics

• Publication date

  1995-06-10

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1006/ABBI.1995.1329PMID 7786040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer

  2004cited by this paper
• Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme.

  1994cited by this paper
• Expression of modified human cytochrome P450 1A1 in Escherichia coli: effects of 5' substitution, stabilization, purification, spectral characterization, and catalytic properties.

  1994cited by this paper
• Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties.

  1994cited by this paper
• Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6.

  1994cited by this paper
• Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities.

  1994cited by this paper
• Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.

  1994cited by this paper
• The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population.

  1994cited by this paper
• Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

  1993cited by this paper
• The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature

  1993cited by this paper
• Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.

  1993cited by this paper
• A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction

  1993cited by this paper
• Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.

  1993cited by this paper
• Metabolic polymorphisms.

  1993cited by this paper
• Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity.

  1993cited by this paper
• Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme.

  1993cited by this paper
• The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.

  1992cited by this paper
• A predictive model for substrates of cytochrome P450-debrisoquine (2D6).

  1992cited by this paper
• Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.

  1992cited by this paper
• The human hepatic cytochromes P450 involved in drug metabolism.

  1992cited by this paper
• Debrisoquine 4-hydroxylase (CYP2D) locus and possible susceptibility to schizophrenia.

  1992cited by this paper
• Reactions and significance of cytochrome P-450 enzymes.

  1991cited by this paper
• Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.

  1991cited by this paper
• Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli.

  1991cited by this paper
• Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.

  1991cited by this paper
• A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation.

  1991cited by this paper
• Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence.

  1991cited by this paper
• Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli.

  1991cited by this paper
• Molecular genetics of the debrisoquin‐sparteine polymorphism

  1991cited by this paper
• Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

  1990cited by this paper
• Identification of the primary gene defect at the cytochrome P450 CYP2D locus

  1990cited by this paper
• Debrisoquine oxidation phenotype and susceptibility to lung cancer.

  1990cited by this paper
• Lung cancer and the debrisoquine metabolic phenotype.

  1990cited by this paper
• Debrisoquine oxidation phenotype and susceptibility to lung cancer.

  1990cited by this paper
• Improved predictions of secondary structures for RNA.

  1989cited by this paper
• On finding all suboptimal foldings of an RNA molecule.

  1989cited by this paper
• Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

  1988cited by this paper
• Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone.

  1988cited by this paper
• Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

  1988cited by this paper
• A single-step large-scale purification of pyruvate oxidase.

  1987cited by this paper
• Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.

  1987cited by this paper
• High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

  1987cited by this paper
• Debrisoquine 4-Hydroxylase: Characterization of a New P450 Gene Subfamily, Regulation, Chromosomal Mapping, and Molecular Analysis of the DA Rat Polymorphism

  1987cited by this paper
• The P450 Gene Superfamily: Recommended Nomenclature

  1987cited by this paper
• Sequence determinants of cytosolic N-terminal protein processing.

  1986cited by this paper
• A simple, one-step purification for cytochrome b from the bc1 complexes of bacteria.

  1986cited by this paper
• Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver.

  1986cited by this paper
• Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.

  1986cited by this paper
• Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

  1986cited by this paper
• Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

  1985cited by this paper
• Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.

  1985cited by this paper
• Debrisoquine‐type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation

  1984cited by this paper
• Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.

  1984cited by this paper
• Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

  1984cited by this paper
• Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

  1984cited by this paper
• Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

  1982cited by this paper
• Phase separation of integral membrane proteins in Triton X-114 solution.

  1981cited by this paper
• Silver staining of proteins in polyacrylamide gels.

  1981cited by this paper
• Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer.

  1981cited by this paper
• Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.

  1980cited by this paper
• Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

  1979cited by this paper
• Hypotensive response to debrisoquine and hydroxylation phenotype.

  1978cited by this paper
• Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography.

  1976cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

  1964cited by this paper

• Reconstitution of human cytochrome P450 activity using a Leishmania cell-free protein expression system

  2025cites this paper
• Heterologous Expression of Recombinant Human Cytochrome P450 (CYP) in Escherichia coli: N-Terminal Modification, Expression, Isolation, Purification, and Reconstitution

  2023cites this paper
• Systematic engineering pinpoints a versatile strategy for the expression of functional cytochrome P450 enzymes in Escherichia coli cell factories

  2023cites this paper
• The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation

  2023cites this paper
• Opportunities for Accelerating Drug Discovery and Development by Using Engineered Drug-Metabolizing Enzymes

  2022cites this paper
• Spectroscopic observations of β-eudesmol binding to human cytochrome P450 isoforms 3A4 and 1A2, but not to isoforms 2C9, 2C19, and 2D6

  2022cites this paper
• Systematic engineering of plant cytochrome P450 system identifies a comprehensive strategy for expression of highly functional P450 enzymes in Escherichia coli

  2022cites this paper
• Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery

  2022cites this paper
• Oxygen Surrogate Systems for Supporting Human Drug-Metabolizing Cytochrome P450 Enzymes

  2020cites this paper
• Engineering highly functional thermostable proteins using ancestral sequence reconstruction

  2018cites this paper
• CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712

  2018influential citation
• Recombinant production of eukaryotic cytochrome P450s in microbial cell factories

  2018cites this paper
• Prospects for Applying Synthetic Biology to Toxicology: Future Opportunities and Current Limitations for the Repurposing of Cytochrome P450 Systems.

  2017cites this paper
• Advances in drug metabolism and pharmacogenetics research in Australia

  2017cites this paper
• Total biosynthesis of opiates by stepwise fermentation using engineered Escherichia coli

  2016cites this paper
• Title Total biosynthesis of opiates by stepwise fermentation usingengineered Escherichia coli

  2016cites this paper
• Characterization of the Ala62Pro polymorphic variant of human cytochrome P450 1A1 using recombinant protein expression.

  2015cites this paper
• Characterization of the Gly45Asp variant of human cytochrome P450 1A1 using recombinant expression.

  2015cites this paper
• Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450.

  2015cites this paper
• Ferrous and ferric state of cytochromes P450 in intact Escherichia coli cells: a possible role of cytochrome P450-flavodoxin interactions.

  2015cites this paper
• Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6

  2014cites this paper
• Functional annotation of orphan human P450 enzymes: Heterologous expression and substrate searches by metabolomic approaches

  2014cites this paper
• A Novel Methodology for Enhanced and Consistent Heterologous Expression of Unmodified Human Cytochrome P450 1B1 (CYP1B1)

  2014cites this paper
• Optimizations to achieve high-level expression of cytochrome P450 proteins using Escherichia coli expression systems.

  2013cites this paper
• Cytochrome P450 Initiates Degradation of cis-Dichloroethene by Polaromonas sp. Strain JS666

  2013cites this paper
• In vitro assessment of the allelic variants of cytochrome P450.

  2012cites this paper
• Cytochrome P450 reductase from Candida apicola: versatile redox partner for bacterial P450s

  2012cites this paper
• Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids[S]

  2012cites this paper
• Steroid transformation by Rhodococcus strains and bacterial cytochrome P450 enzymes

  2011cites this paper
• Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Adduction

  2011cites this paper
• Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Adduction

  2011cites this paper
• Biooxidation with Cytochrome P450 Monooxygenases

  2010cites this paper
• Molecular cloning and enzymatic characterization of sheep CYP2J

  2010cites this paper
• Catalysis with Cytochrome P450 Monooxygenases

  2010cites this paper
• Mechanisms of the Extreme Sensitivity of Turkeys to Aflatoxin B1

  2010cites this paper
• Self-Sufficient Catalytic System of Human Cytochrome P450 4A11 and NADPH-P450 Reductase

  2009influential citation
• Biosynthesis of plant isoprenoids: perspectives for microbial engineering.

  2009cites this paper
• Quantitation of Human Cytochrome P450 2D6 Protein with Immunoblot and Mass Spectrometry Analysis

  2009cites this paper
• METABOLIC ENGINEERING OF SACCHAROMYCES CEREVISIAE FOR THE PRODUCTION OF BENZYLISOQUINOLINE ALKALOIDS

  2009cites this paper
• Membrane integration of recombinant human P450 forms

  2009cites this paper
• Engineering cytochrome p450 enzymes.

  2008cites this paper
• Structural Basis for Multimeric Heme Complexation through a Specific Protein-Heme Interaction

  2008cites this paper
• Prozessentwicklung und Produktion von Wirkstoff-Metaboliten durch Ganzzellbiotransformation im Gramm-Maßstab mit humanem Cytochrom P450 exprimiert in E. coli

  2008cites this paper
• Production of benzylisoquinoline alkaloids in Saccharomyces cerevisiae.

  2008cites this paper
• Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design.

  2006cites this paper
• Molecular cloning and expression of a novel cytochrome p450 from turkey liver with aflatoxin b1 oxidizing activity.

  2006cites this paper
• Purification of Cytochromes P450 : Products of Bacterial Recombinant Expression Systems.

  2006cites this paper
• Functional expression of human cytochrome P450 enzymes in Escherichia coli.

  2006cites this paper
• CYP2D6-dependent bufuralol 1'-hydroxylation assayed by reverse-phase ion-pair high-performance liquid chromatography with fluorescence detection.

  2006cites this paper
• Biotransformation of the polycyclic aromatic hydrocarbon pyrene in the marine polychaete Nereis virens

  2005cites this paper
• Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.

  2005cites this paper
• Functional characterisation of an engineered multidomain human P450 2E1 by molecular Lego

  2005cites this paper
• Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.

  2005cites this paper
• Characterisation of two novel CYP4 genes from the marine polychaete Nereis virens and their involvement in pyrene hydroxylase activity.

  2005cites this paper
• Optimization of an in vivo plant P450 monooxygenase system in Saccharomyces cerevisiae

  2004cites this paper
• Expression of human aromatase (CYP19) in Escherichia coli by N-terminal replacement and induction of cold stress response.

  2003cites this paper
• Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.

  2003cites this paper
• Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group.

  2003cites this paper
• Characteristics of cytochrome P450-catalysed drug metabolism with focus on a black Tanzanian population

  2003cites this paper
• Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes.

  2002cites this paper
• Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

  2002cites this paper
• A Major CYP2D6 Autoepitope in Autoimmune Hepatitis Type 2 and Chronic Hepatitis C is a Three-dimensional Structure Homologous to Other Cytochrome P450 Autoantigens

  2002cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

  2002cites this paper
• Studies of the structure of cytochrome P450 4A1

  2002cites this paper
• Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase: prediction of metabolism and toxicity of drugs in humans.

  2002cites this paper
• Oxidation of Methoxyphenethylamines by Cytochrome P450 2D6

  2002cites this paper
• Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6.

  2002cites this paper
• OF TAMOXIFEN BY RECOMBINANT HUMAN CYTOCHROME P 450 ENZYMES : FORMATION OF THE 4-HYDROXY , 4-HYDROXY AND N-DESMETHYL METABOLITES AND ISOMERIZATION OF trans-4-HYDROXYTAMOXIFEN

  2002cites this paper
• Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.

  2001cites this paper
• Pharmacogenetics

  2001cites this paper
• Exploiting the Versatility of Human Cytochrome P450 Enzymes: The Promise of Blue Roses From Biotechnology

  2001cites this paper
• Diversity in Mechanisms of Substrate Oxidation by Cytochrome P450 2D6

  2001cites this paper
• Coumarin substrates for cytochrome P450 2D6 fluorescence assays.

  2001cites this paper
• Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.

  2001cites this paper
• The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.

  2000cites this paper
• Functional expression of horseradish peroxidase in Saccharomyces cerevisiae and Pichia pastoris.

  2000cites this paper
• Enhanced expression of CYP1B1 in Escherichia coli.

  2000cites this paper
• Cloning and expression of cytochrome P450 enzymes catalyzing the conversion of tyrosine to p-hydroxyphenylacetaldoxime in the biosynthesis of cyanogenic glucosides in Triglochin maritima.

  2000cites this paper
• Oxidation of indole by cytochrome P450 enzymes.

  2000cites this paper
• Formation of indigo by recombinant mammalian cytochrome P450.

  1999cites this paper
• High yield purification and characterization of engineered human P450 1A2 and generation of immuno-inhibitor antibodies.

  1999cites this paper
• Strategies to enhance the coexpression of cytochrome P450 2E1 and reductase in bacteria.

  1999cites this paper
• Purification of Cytochrome P‐450 Enzymes

  1999cites this paper
• In Vivo and In Vitro Recombinant DNA Technology as a Powerful Tool in Drug Development

  1999cites this paper
• Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies.

  1999cites this paper
• Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment.

  1999cites this paper
• Applications of Heterologous Expressed and Purified Human Drug-Metabolizing Enzymes: An Industrial Perspective

  1999cites this paper
• Flavodoxin as a model for the P450-interacting domain of NADPH cytochrome P450 reductase.

  1999cites this paper
• Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.

  1998cites this paper
• Expression and characterization of dog CYP2D15 using baculovirus expression system.

  1998cites this paper
• Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.

  1998cites this paper
• CHANGE IN SUBSTRATE ENANTIO AND REGIOSELECTIVITY FOR VARIOUS HETEROLOGOUS CYP2D6 EXPRESSION SYSTEMS

  1998cites this paper
• High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli.

  1998cites this paper
• Identification of the Binding Site on Cytochrome P450 2B4 for Cytochrome b 5 and Cytochrome P450 Reductase*

  1998cites this paper
• Isolation of partially purified P450 2D18 and characterization of activity toward the tricyclic antidepressants imipramine and desipramine.

  1998cites this paper
• Purification of Cytochromes P450

  1998cites this paper
• Recombinant human cytochrome P450 1B1 expression in Escherichia coli.

  1998cites this paper
• HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN BACTERIA: REAGENTS TO PROBE MOLECULAR INTERACTIONS IN TOXICOLOGY

  1998cites this paper
• In vitro assessment of human cytochrome P450.

  1998cites this paper